RK-33

• Description :

  RK-33 is an RNA helicase inhibitor against DDX3, and inhibits its helicase activity.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  DNA/RNA Synthesis; SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/RK-33.html

• Purity :

  99.63

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1N(CC2=CC=C(OC)C=C2)C3=NC=NC4=C(N=CN4CC5=CC=C(OC)C=C5)C3=N1

• Molecular Formula :

  C23H20N6O3

• Molecular Weight :

  428.44

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Xie M, et al. RK-33 radiosensitizes prostate cancer cells by blocking the RNA helicase DDX3. Cancer Res. 2016 Sep 12.|[2]Bol GM, e tal. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3. Cancer Chemother Pharmacol. 2015 Oct;76 (4) :821-7.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1070773-09-9]